Austin, Texas-based molecular diagnostics firm Vermillion hopes to raise as much as $31.5 million through the sale of 8 million shares of stock. Part of the proceeds will go toward improving sales and reimbursements for the company's OVA1 assay, which is used to distinguish malignant from benign ovarian tumors.
Vermillion targets $31.5M from funding round
SmartBrief Job Listings for Health Care
|Compliance and Ethics Director||
Sysmex America, Inc.
|Director, Site Quality Management||
|Palm Springs, CA|
|Compliance Officer-Medical Products||
W. L. Gore